Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung CancerKoji Haratani, Kazuhiko Nakagawa, Hidetoshi Hayashi et al.|JAMA Oncology|2017Cited by 1k
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatmentKoji Haratani, Kazuhiko Nakagawa, Kazuko Sakai et al.|Annals of Oncology|2017Cited by 294
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung CancerKohsuke Isomoto, Kazuhiko Nakagawa, Koji Haratani et al.|Clinical Cancer Research|2020Cited by 244
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with NivolumabJunko Tanizaki, Kazuhiko Nakagawa, Koji Haratani et al.|Journal of Thoracic Oncology|2017Cited by 227
B7-H3 Negatively Modulates CTL-Mediated Cancer ImmunityKimio Yonesaka, Kazuhiko Nakagawa, Koji Haratani et al.|Clinical Cancer Research|2018Cited by 169